Posted 2/29/2024, 11:42:00 AM
Viking Therapeutics Stock Soars 120% on Positive Weight Loss Drug Trial Results, But Questions Remain on Long-Term Outlook
- Viking Therapeutics' share price soared 120% after positive phase 2 trial results for its weight loss drug candidate VK2735
- VK2735 showed promising efficacy in helping patients lose up to 13.1% of body weight over 13 weeks
- The weight loss drug market is rapidly growing and could be worth $100B by 2030
- It may be difficult for Viking to compete with big pharma companies like Lilly and Novo Nordisk
- After such a huge one-day gain, Viking's stock price may already reflect the good news about VK2735